Clinical Trials Bullish 7

Hope Medicine Doses First Patient in Phase III Endometriosis Trial for HMI-115

· 3 min read · By Biotech Intelligence Brief Editorial
Share

Key Takeaways

  • Hope Medicine has officially initiated its Phase III clinical trial for endometriosis, dosing the first patient with HMI-115.
  • This milestone marks a significant advancement in the development of a first-in-class prolactin receptor antagonist designed to address the high unmet need in women's health.

Mentioned

Hope Medicine company Bayer company BAYRY HMI-115 product

Key Intelligence

Key Facts

  1. 1Hope Medicine has dosed the first patient in its global Phase III clinical trial for endometriosis.
  2. 2The investigational drug, HMI-115, is a first-in-class monoclonal antibody targeting the prolactin receptor (PRLR).
  3. 3HMI-115 was originally licensed from Bayer in 2019 for global development and commercialization.
  4. 4Endometriosis affects approximately 190 million women worldwide, with limited non-hormonal treatment options.
  5. 5The Phase III trial aims to confirm the efficacy and safety of HMI-115 in reducing endometriosis-associated pain.
Clinical Outlook

Analysis

The initiation of Hope Medicine’s Phase III clinical trial for endometriosis represents a pivotal moment for both the company and the broader landscape of women’s health. Endometriosis, a chronic condition where tissue similar to the lining of the uterus grows outside the womb, affects approximately 10% of women of reproductive age globally. Despite its prevalence, the therapeutic market has long been dominated by hormonal therapies that often carry significant side effects, such as bone density loss and menopausal symptoms. Hope Medicine’s lead candidate, HMI-115, offers a potentially transformative alternative by targeting the prolactin receptor (PRLR) pathway rather than traditional estrogen suppression.

The transition into Phase III testing follows promising earlier data suggesting that HMI-115 can effectively manage the debilitating pain associated with endometriosis while maintaining a favorable safety profile. By blocking the prolactin receptor, the monoclonal antibody aims to inhibit the growth and inflammatory response of endometriotic lesions directly. This mechanism of action is distinct from current standards of care, such as GnRH antagonists like elagolix (Orilissa) or relugolix (Myfembree), which focus on systemic hormone regulation. If successful, HMI-115 could become the first non-hormonal biologic therapy approved for this indication, providing a critical option for patients who cannot tolerate or do not respond to existing treatments.

Endometriosis, a chronic condition where tissue similar to the lining of the uterus grows outside the womb, affects approximately 10% of women of reproductive age globally.

Hope Medicine’s journey with HMI-115 is also a notable example of successful asset licensing and cross-border development. The drug was originally discovered by Bayer, and Hope Medicine secured the global rights to develop and commercialize the therapy in 2019. Since then, the company has aggressively pushed the clinical program forward, navigating the complexities of global regulatory requirements. The start of this Phase III trial underscores the company's ability to execute late-stage clinical operations and its commitment to addressing chronic diseases with high morbidity. For investors and industry observers, this milestone validates Hope Medicine's strategic focus on high-value, first-in-class assets in underserved therapeutic areas.

What to Watch

The competitive landscape for endometriosis is currently undergoing a shift as more companies explore non-hormonal pathways. However, Hope Medicine holds a significant lead in the prolactin receptor space. The success of this Phase III trial will depend on its ability to demonstrate consistent efficacy in pain reduction across a diverse patient population while ensuring that long-term administration does not interfere with other physiological processes regulated by prolactin. Regulatory agencies, including the FDA and NMPA, will be looking closely at the durability of the treatment effect and the impact on patients' quality of life, which is often severely compromised by the disease.

Looking ahead, the completion of this Phase III trial will be the primary catalyst for Hope Medicine’s valuation and potential market entry. The company is expected to provide interim updates as enrollment progresses across global sites. Should the data remain robust, HMI-115 could pave the way for a new era in endometriosis management, shifting the focus from symptom suppression to targeted lesion control. This development also highlights the growing importance of specialized biotech firms in revitalizing legacy assets from large pharmaceutical companies to meet specific patient needs.

Timeline

Timeline

  1. Licensing Agreement

  2. Phase II Completion

  3. Phase III Initiation

Cite This Page

"Hope Medicine Doses First Patient in Phase III Endometriosis Trial for HMI-115." Biotech Intelligence Brief, March 25, 2026. https://getbiobrief.com/story/hope-medicine-phase-3-endometriosis-trial-hmi-115

Related Stories

Clinical Trials

181 NCI Grants Worth $317M Canceled, Halting Cancer Trials

The cancellation of 181 NCI grants totaling $317 million in early 2025 has stopped cancer disparity clinical trials in their tracks, according to an AACR report. The biotech and pharma pipelines face disruption as critical early-stage research evaporates.

Clinical Trials

NNVC's NV-387 Phase II Sets Course as First Oral Ebola Therapy Contender

NanoViricides (NYSE American: NNVC) has crossed a major regulatory hurdle with DRC ethics committee approval for its Phase II trial of NV-387 oral gummies for Ebola. The company leverages its nanoviricide platform against an underserved Bundibugyo strain, positioning itself uniquely in the infectious disease space with a potential first-in-class oral antiviral.

Clinical Trials

CaringAI Study Validates AI Cognitive Screening with 80% Clinician Concordance

At AAIC 2026, CaringAI presented research showing 80% concordance between its AI telephone assessment and clinical review, providing early validation for a digital biomarker in cognitive screening.

Clinical Trials

Cognivia-Mayo Collaboration Targets 3 Behavioral Drivers to Improve Trial Retention

Cognivia and Mayo Clinic are zeroing in on non-adherence, missed appointments, and trial dropout—three behavioral factors that inflate clinical trial costs and delay drug development. By making patient behavior measurable, the partnership could help biopharma sponsors de-risk studies and improve real-world evidence.

How we covered this story

Every story in our biotech coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.

Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the biotech space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.

Signal on this pageWhat it tells you
Verified by N sourcesIndependent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly.
Impact score (1-10)Regulatory + financial + operational weight. 8+ signals an experienced-operator action item.
SentimentFive-tier classification trained on labeled biotech-specific corpora.
TimelineWhere applicable, the related-events sequence that contextualizes today's development.